Actionable news
0
All posts from Actionable news
Actionable news in LOW: LOWE'S COMPANIES Inc,

Top Analysts Love These 5 Buy-Rated Dividend Aristocrats for 2017

The pricier the market gets, the more it makes sense to stay with industry leaders, especially those that have paid and raised their dividends consistently. One of the most famous groups of stocks that can lay claim to these areas is the Dividend Aristocrats. Those are S&P 500 constituents that have increased their dividend payouts for 25 consecutive years. The companies that make up the Dividend Aristocrats span 10 different business sectors, with both growth and value holdings.

We cross-referenced the Dividend Aristocrats with the Merrill Lynch research universe and found five stocks that are rated Buy at the firm and look like solid stocks to own for 2017. Given the expensive levels the market is trading at, it may make sense to buy partial positions now and see if we don’t get a first quarter pull-back.

Abbott Laboratories

Shares of this top pharmaceutical stock with very solid growth potential are down over 10% since last August. Abbott Laboratories (NYSE: ABT) is a leading diversified global health care company that develops, manufactures and markets branded generics, medical devices, nutritional products and diagnostic solutions.

The company recently agreed to acquire the equity in Minnesota-based Tendyne Holdings that it does not already own for $250 million plus future payments tied to regulatory milestones. Wall Street likes the purchase and the way the company is putting its substantial balance sheet to work.

The company also offers a diversified large cap play as earnings are split between five well-positioned business segments: Nutritionals (31.0% of revenues), Vascular (13.0%), Generic Pharmaceuticals (20.0%) and Diagnostics (25.5%) and Diabetes (10.5%).

Last year, CEO Miles White, who has been at the firm for over three decades, bought a stunning $45.5 million worth of company stock, which added to his already substantial holdings. The purchase made him one of the top 100 shareholders.

Abbott Labs investors receive a 2.62% dividend. The Merrill Lynch price target for the stock is $50, and the Wall Street consensus target is $46.69. The shares closed last Friday at $40.46.

Chevron

This stock is very solid story for investors looking to stay long the energy sector, and it is a...


More